AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.
AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.
“This integrated company will be able to shape the future of mass spectrometry in ways far greater than what we have already achieved,” said Laura Lauman, the company’s president, in a statement. According to Lauman, bringing the former joint venture together will enable the company to “keep pace with the dynamic needs of the life science industry.”
The company provides instrumentation, software and services used in a number of life science applications, including drug discovery and development, disease studies and food and environmental safety. These include integrated LC–MS–MS platforms for small molecule analysis, contaminant identification and biomarker validation, as well as MALDI TOF/TOF systems for protein biomarker discovery.
For more information about the company go to www.absciex.com
Analyzing Effects of Adverse Cardiovascular Events on Chronic Kidney Disease with HPLC
March 13th 2025Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse cardiovascular outcomes in individuals with chronic kidney disease (CKD). Plasma sphingosine-1-phosphate (S1P) levels were measured by high performance liquid chromatography (HPLC).
New Study Investigates Optimizing Extra-Column Band Broadening in Micro-flow Capillary LC
March 12th 2025Shimadzu Corporation and Vrije Universiteit Brussel researchers recently investigated how extra-column band broadening (ECBB) can be optimized in micro-flow capillary liquid chromatography.